<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534870</url>
  </required_header>
  <id_info>
    <org_study_id>M13-769</org_study_id>
    <nct_id>NCT02534870</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects</brief_title>
  <official_title>Multiple-Dose Pharmacokinetics, Safety and Tolerability of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics and safety of multiple oral doses
      of ABT-450/ritonavir/ABT-267 and ABT-333 when co-administered under non-fasting conditions in
      healthy Chinese adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of ABT-450</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of ABT-267</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of ABT-333</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Ritonavir</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of ABT-450</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of ABT-267</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of ABT-333</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Ritonavir</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14; and 36, 48, and 72 hours after the morning dose on Study Day 14</time_frame>
    <description>Tmax is the time it takes for a drug to achieve Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of ABT-450</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of ABT-267</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of ABT-333</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough) of Ritonavir</measure>
    <time_frame>Prior to the morning dose on Study Days 7, 9, 11, 13 and 14; 24 hours after Day 14 dose</time_frame>
    <description>Ctrough is the lowest concentration of a drug in the blood after administration in a dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, 12, 15, 18, and 24 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333</measure>
    <time_frame>Prior to the morning dose (0 hour) and 1, 2, 3, 4, 6, 9, and 12 hours after the morning dose on Study Days 1 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Daily for approximately 20 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>ABT-450/r/ABT-267 + ABT-333</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-450/r/ABT-267</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 + ABT-333</arm_group_label>
    <other_name>Paritaprevir/Ritonavir/Ombitasvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-333</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ABT-450/r/ABT-267 + ABT-333</arm_group_label>
    <other_name>Dasabuvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Participant must be Chinese (i.e., of Chinese ancestry).

        If female, participant must be either postmenopausal for at least 2 years, surgically
        sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or practicing
        at least one of the following methods of birth control with male partner(s): total
        abstinence from sexual intercourse as the preferred life style of the subject, periodic
        abstinence is not acceptable; vasectomized partner(s); hormonal contraceptives (oral,
        parenteral or transdermal) for at least 3 months prior to study drug administration;
        intrauterine device (IUD); or double-barrier method (condoms, contraceptive sponge, or
        diaphragm with spermicidal jellies or creams)

        Hormonal contraceptives, including but not limited to oral, topical, injectable or
        implantable varieties, may not be used during the study.

        If male, the participant must be surgically sterile or practicing at least 1 of the
        following methods of contraception, and refrain from sperm donation, from initial study
        drug administration until 90 days after the last dose of study drug: partner(s) using an
        IUD; partner(s) using oral, injected, intravaginal, or implanted methods of hormonal
        contraceptives; participant and/or partner(s) using double-barrier method (condoms,
        contraceptive sponge, diaphragm with spermicidal jellies or creams, or vaginal ring); or
        total abstinence from sexual intercourse as the preferred life style of the subject;
        periodic abstinence is not acceptable

        Body Mass Index (BMI) is â‰¥ 18 to &lt; 30 kg/m^2.

        A condition of general good health, based upon the results of a medical history, physical
        examination, vital signs, laboratory profile, a 12-lead electrocardiogram (ECG) and chest
        x-ray (CXR).

        Exclusion Criteria: Use of any medications (prescription and over-the-counter), vitamins
        and/or herbal supplements within the 2-week period prior to the first dose of study drug
        administration or within 10 half-lives of the respective medication, whichever is longer.

        History of epilepsy, any clinically significant cardiovascular, respiratory (except mild
        asthma), renal, hepatic, gastrointestinal, hematologic, neurologic, thyroid, or any
        uncontrolled medical illness or psychiatric disease or disorder.

        Clinically significant abnormal ECG: ECG with QT interval corrected for heart rate using
        Fridericia's correction formula (QTcF) &gt; 450 msec in females and &gt; 430 msec in males, or
        ECG with second or third degree atrioventricular block.

        Previous exposure to more than a single dose of ABT-450/r/ABT-267, or ABT-333 within the
        past 12 weeks, or previous participation in this study.

        Consideration by the investigator, for any reason, that the subject is an unsuitable
        candidate to receive ABT-450, ritonavir, ABT-267, or ABT-333.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Luo, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137655</name>
      <address>
        <city>Shanghai</city>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

